Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $195.00.

ASND has been the subject of several recent research reports. Citigroup increased their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. TD Cowen lowered their target price on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Jefferies Financial Group upped their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the first quarter worth about $36,000. GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares in the last quarter. Bessemer Group Inc. grew its holdings in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the last quarter. Barometer Capital Management Inc. acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $126,000. Finally, Searle & CO. purchased a new position in Ascendis Pharma A/S during the second quarter worth $205,000.

Ascendis Pharma A/S Trading Up 1.2 %

ASND stock opened at $142.67 on Tuesday. The company has a market capitalization of $8.31 billion, a P/E ratio of -14.85 and a beta of 0.64. The business has a 50 day simple moving average of $135.44 and a 200-day simple moving average of $136.41. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Research analysts predict that Ascendis Pharma A/S will post -7.15 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.